葛兰素史克行贿丑闻继续发酵

    中国政府指控葛兰素史克（GlaxoSmithKline）前任中国区负责人马克锐为提高药品销量而行贿医生和医疗机构。

    中国公安部（the Ministry of Public Security）经济犯罪侦察局副局长高峰指出，马克锐运营着一张“巨大的行贿网”。

    新华社称，在马克锐的经营下，这家公司中国区的营业额从2009年的39亿元上升到了2012年的69亿元。高峰说：“葛兰素史克的行贿活动贯穿了它在中国的整个业务运营。”

    据悉，为寻求行贿资金来源，葛兰素史克大幅提升了药物成本，它的药品在中国的售价甚至达到了其他国家的7倍。

    葛兰素史克在声明中回应相关指控时指出：“我们非常严肃地对待这些指控。它们十分令人担忧，而且也与葛兰素史克的价值观背道而驰。我们将继续就此事全面配合政府机构。”

    这一举措意味着中国计划采取更为强硬的措施来打击外国高管的腐败行为。中国最近在国内政府官员以及本土高管的腐败问题上采取了强硬的立场，但腐败仍然是一个大问题。

    新华社称，除了于2013年7月离任的马克锐之外，中国政府还指控这家公司的高管张国维和赵虹燕行贿北京和上海地区的官员。案件于去年6月开始调查，还涉及其他46名人员。

    高峰说，葛兰素史克还曾试图阻挠执法机关的调查。目前尚不清楚马克锐将面临什么样的惩罚，也不知道中国政府将在什么时候会正式他，或者说到底会不会起诉。（财富中文网）

    译者：翔

    Chinese authorities have accused GlaxoSmithKline's former China chief, Mark Reilly, of ramping up drug sales by bribing doctors and healthcare organizations.

    Gao Feng, deputy director of China's Ministry of Public Security's economic crimes unit, said Reilly operated a "massive bribery network."

    Under Reilly, revenue in China rose from 3.9 billion yuan in 2009 to 6.9 billion in 2012, according to the news agency Xinhua. "GSK's bribery activities ran through its entire operations in China," Gao said.

    In order to fund the bribery, Glaxo (GSK) allegedly bumped up drug costs, charging as much as seven times more than in other countries.

    "We take the allegations that have been raised very seriously," Glaxo said in a statement in response to the accusation. "They are deeply concerning to us and contrary to the values of GlaxoSmithKline. We will continue to fully co-operate with the authorities in this matter."

    The action signals China's plans to take aggressive action against corruption by foreign executives. The country has recently taken a tougher stance on corruption by its own political leaders and local executives, but corruption remains a huge problem.

    Along with Reilly, who left Glaxo in July 2013, Chinese officials accused fellow executives Zhang Guowei and Zhao Hongyan, of bribing officials in Beijing and Shanhai, Xinhua said. An additional 46 others have been implicated in the case, which began last June.

    Gao said that Glaxo also had tried to disrupt the law enforcement investigation. It's unclear what kind of punishment Reilly faces or when he will be formally indicted, if at all.